 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2020 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced positive initial results from the Phase 1 UNIVERSAL study of ALLO-715 in relapsedrefractory multiple myeloma MM. Data were presented at an oral session of the American Society of Hematology ASH annual meeting. This study utilizes ALLO-647, Allogenes anti-CD52 monoclonal antibody mAb, as a part of its differentiated lymphodepletion regimen. 